Diagnostic difficulties in rectosigmoid lesions.

V. Blaha,H. C. Saltzstein

DOI: https://doi.org/10.1007/BF03005027

1949-06-01

The American Journal of Digestive Diseases

Abstract:

What problem does this paper attempt to address?

EphA 3 , induced by PC1 / PrLZ , contributes to the malignant progression of prostate cancer

Ruiqin Wu,Hongtao Wang,Jian Wang,Peng Wang,Fang Huang,Bangxiang Xie,Yali Zhao,Li Shanhu,Jianguang Zhou

Abstract:Our previous study revealed the potential linkage of PC-1/PrLZ, a novel isolated prostate-specific gene, to the progression of prostate cancer (PCa) in vitro and in vivo. To gain more insight into the mechanism of PC-1-induced promotion of PCa, expression analysis of differential genes induced by PC-1 was scanned by microarray. Among all the differentially expressed genes, EphA3 was altered to the greatest extent. EphA3 has been identified to be associated with multiple tumor progression. However, little is known concerning the function of EphA3 in PCa. In the present study, we aimed to ascertain whether EphA3 is induced by PC-1 and the functional significance of EphA3 expression in PCa. We found that overexpression of PC-1 increased the amount of EphA3 and that knockdown of PC-1 led to a decrease in EphA3 in PCa cells. The functional significance and mechanisms by which EphA3 contributes to PCa was investigated in vitro using cell lines, and in vivo using a mouse model and clinical specimens. The results showed that EphA3 enhanced the proliferation and survival of LNCaP cells and suppression of EphA3 inhibited the survival of C4-2B cells. EphA3 enhanced the tumor development of LNCaP cells in null mice. A positive correlation between the levels of EphA3 and the Gleason grade of PCa was identified in clinical PCa specimens. In addition, cellular localization changed with Gleason grade. We further detected that EphA3 increased phosphorylation of Akt (Ser473 and Thr308), indicating that EphA3 activated the Akt pathway. Taken together, EphA3 was induced by PC-1 and contributed to the malignant progression of prostate cancer. Our results provide the first demonstration that EphA3 is a novel promoter of human prostate cancer development and progression.
Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA

Derek Wong,Ping Luo,Leslie E Oldfield,Haifan Gong,Ledia Brunga,Ron Rabinowicz,Vallijah Subasri,Clarissa Chan,Tiana Downs,Kirsten M Farncombe,Beatrice Luu,Maia Norman,Julia A Sobotka,Precious Uju,Jenna Eagles,Stephanie Pedersen,Johanna Wellum,Arnavaz Danesh,Stephenie D Prokopec,Eric Y Stutheit-Zhao,Nadia Znassi,Lawrence E Heisler,Richard Jovelin,Bernard Lam,Beatriz E Lujan Toro,Kayla Marsh,Yogi Sundaravadanam,Dax Torti,Carina Man,Anna Goldenberg,Wei Xu,Patrick Veit-Haibach,Andrea S Doria,David Malkin,Raymond H Kim,Trevor J Pugh

DOI: https://doi.org/10.1158/2159-8290.CD-23-0456

2024-01-12

Abstract:People with Li-Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates a targeted gene panel, shallow whole-genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 LFS patients. Multimodal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis and was able to detect cancer-associated signal(s) in carriers prior to diagnosis with conventional screening (positive predictive value = 67.6%, negative predictive value = 96.5%). Although adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with LFS. Significance: By utilizing an integrated cell-free DNA approach, liquid biopsy shows earlier detection of cancer in patients with LFS compared with current clinical surveillance methods such as imaging. Liquid biopsy provides improved accessibility and sensitivity, complementing current clinical surveillance methods to provide better care for these patients. See related commentary by Latham et al., p. 23. This article is featured in Selected Articles from This Issue, p. 5.
Abstract 6198: TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum

Nicholas W. Fischer,Brianne Laverty,Ran Kafri,Kara N. Maxwell,Emma R. Woodward,Christian Kratz,David Malkin

DOI: https://doi.org/10.1158/1538-7445.am2024-6198

IF: 11.2

2024-03-24

Cancer Research

Abstract:Li-Fraumeni syndrome (LFS) is a highly penetrant cancer predisposition disorder caused by germline variants in the TP53 tumor suppressor gene. LFS has recently been redefined as a 'spectrum' disorder to reflect the highly variable cancer types with largely unpredictable ages-of-onset and disease severity. The broad functional gradient associated with different TP53 variants is thought to contribute to LFS heterogeneity, although it is still poorly understood and there is an unmet clinical need for risk stratification strategies to improve variant interpretation and patient care. Here, we performed an unsupervised cluster analysis leveraging p53 mutagenesis datasets (Kato et al., 2003 & Giacomelli et al., 2018) that revealed five TP53 mutational clusters with unique mutation patterns, structural features, and functional consequences. Stratifying germline carriers based on the five clusters exposed important clinical characteristics to consider for patient management, such as ages-of-onset, tumor type development, and survival outcomes. In particular, we discovered an osteosarcoma-prone subgroup comprised of monomeric mutant p53 carriers with aggressive cancer phenotypes. We also identified a cluster of TP53 variants found more often in non-cancer and healthy older populations, and carriers of these variants that developed cancer had less "LFS-like" phenotypes including an older age-of-onset and a significantly higher frequency of colorectal cancers. Remarkably, our TP53 variant clustering strategy could also stratify breast cancer survival among germline carriers. This work provides a new framework to delineate the LFS spectrum toward the development of machine learning-based approaches for personalized cancer surveillance plans. Citation Format: Nicholas W. Fischer, Brianne Laverty, Ran Kafri, Kara N. Maxwell, Emma R. Woodward, Christian Kratz, David Malkin. TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6198.

oncology
Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome

Claire Freycon,Laura Palma,Crystal Budd,Frederic Coulombe,Leora Witkowski,Pierre Hainaut,William D Foulkes,Catherine Goudie

DOI: https://doi.org/10.1007/s10689-024-00419-7

2024-09-11

Abstract:Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with germline pathogenic/likely pathogenic variants in TP53. Genotype-phenotype correlations are progressively being characterized in LFS with certain TP53 variants associated with attenuated penetrance and phenotypes. We report on a family harboring a TP53 p.R181H variant presenting with a restricted cancer phenotype in adulthood. The proband was a female with breast cancer at the age of 71 years who had three first degree relatives also diagnosed with breast cancer after the age of 40 years (mother, two sisters). Of the nine individuals harboring the variant (6 genetically confirmed, 3 obligate heterozygous), six have not developed malignancies at this time (age range: 36-42). No childhood-onset cancers were reported in this family. A concomitant literature review identified 51 additional individuals harboring the p.R181H variant in TP53, presenting a tumor phenotype dominated by breast cancer. Rare occurrences of other adult-onset cancers (prostate, colorectal and thyroid) and only few childhood onset cancer were documented. These observations are consistent with functional analysis showing that p.R181H retains partial p53 function and suggesting possible reduced cancer penetrance, particularly in the pediatric setting.
Abstract 810: Enrichment and Screening of LFS Patients by Analyzing TP53 Germline Mutations of a Chinese Cancer Cohort

Changyu Lu,Fang Yu,Fachen Zhou,Yuntong Liu,Hongchuan Niu,Kai Li,Tao Ma,Xiaoyan Zhang

DOI: https://doi.org/10.1158/1538-7445.am2021-810

IF: 11.2

2021-01-01

Cancer Research

Abstract:Background: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant inherited cancer syndrome; clinical diagnosis of it is mainly based on familial and personal history of cancer. Currently, most clinicians are lack of knowledge and experience of this rare disease, resulting in a difficulty to identify it. Consider that this is a rare tumor-type syndrome and 60-80% of the patients have germline variants of TP53, herein, we analyzed germline pathogenic/likely pathogenic (P/LP) TP53 variants in a Chinese tumor cohort with unknown familial history, and successfully established an analysis process to better screen for LFS patients. Methods: We retrospectively analyzed the germline TP53 mutations of a total of 19,226 Chinese tumor patients with unknown familial history. The screening process of LFS patients was as follows: 1) Germline P/LP TP53 variants must satisfy P/LP in any of the three databases: UMD_TP53, ClinVar or HGMD. It also must be defined as “non-functional” mutations in IARC database which includes all TP53 germline mutations of clinically determined LFS patients; 2) Follow up the familial and personal histories of patients with germline P/LP TP53 variants. Results: After screening, 26 germline P/LP TP53 variants were obtained, which involved 54 patients, mainly in brain cancer (34 pts) and lung cancer (9 pts). The median age of these 34 brain cancer patients was younger than that of 5,845 brain cancer patients in the cohort (28 vs. 44 year-old). Yet no such phenomenon was observed in lung cancer. It is necessary for young brain cancer patients to detect germline TP53 mutations. We then analyzed the relationship between germline P/LP TP53 variants and LFS in the 54 patients. According to the Chompret criterion of LFS, two patients who respectively had adrenocortical carcinoma (R175H of TP53) and choroid plexus carcinoma (G245S) were both LFS patients regardless of whether they had a familial history. We finally obtained follow-up information of 17 patients. Among them, four brain cancer patients (R248Q/R158H/C238Y/M237I), one lung cancer patient (R175H) and one leiomyosarcoma patient (R213Q) had family members who had cancers before 46-year-old. Another brain cancer patient (G245S; 1/17) had more than one cancer before 46-years-old. Hence, these seven patients (7/17; 41.18%) were also defined as LFS patients by the Chompret criterion. In total, 9 patients had LFS. It shows a high positive detection rate in our cohort by our analysis process. Conclusions: We have established an analysis process based on germline P/LP TP53 variants, which can efficiently screen for LFS patients in clinic. Citation Format: Changyu Lu, Yu Fang, Fachen Zhou, Yuntong Liu, Hongchuan Niu, Kai Li, Tonghui Ma, Xiaoyan Zhang. Enrichment and screening of LFS patients by analyzing TP53 germline mutations of a Chinese cancer cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 810.
Distinct genomic and immunologic tumor evolution in germline driven breast cancers

Nabamita Boruah,David Hoyos,Renyta Moses,Ryan Hausler,Heena Desai,Anh N Le,Madeline Good,Gregory Kelly,Ashvathi Raghavakaimal,Maliha Tayeb,Mohana Narasimhamurthy,Abigail Doucette,Peter Gabriel,Michael J. Feldman,Jinae Park,Miguel Lopez de Rodas,Kurt A. Schalper,Shari B. Goldfarb,Anupma Nayak,Arnold J. Levine,Benjamin D. Greenbaum,Kara N. Maxwell

DOI: https://doi.org/10.1101/2024.04.03.588009

2024-04-07

Abstract:Pathogenic germline alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of with no recurrent oncogenic variants except (HER2) amplification. Compared to sporadic BC, and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes and failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue. LFS-BC had lower CD8+ T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from to invasive BC was marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.

Genetics
Abstract 1533: Characterizing tumor-immune surveillance in Li-Fraumeni syndrome

Camilla Giovino,Nicholas Fischer,Noel Ong,Ashby Kissoondoyal,Ran Kafri,David Malkin

DOI: https://doi.org/10.1158/1538-7445.am2024-1533

IF: 11.2

2024-03-28

Cancer Research

Abstract:Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome associated with germline TP53 mutations and increased lifetime risk of developing multiple cancers. p53, the protein encoded by TP53, plays a role in regulating various aspects of immune cell biology. Accordingly, inactivation of p53 in tumor cells shapes interactions with the immune system and influences the anti-tumor immune response. Mutation or deletion of p53 in immune cells also favors tumor development and progression. However, to date, a comprehensive study of immune cell populations and the anti-tumor immune response has not been undertaken in the context of LFS. We hypothesized that germline TP53 mutation carriers possess dysfunctional immune cells and/or immune responses, supporting LFS-associated tumor progression. Our preliminary data indicate a profound defect in tumor-immune surveillance in an LFS murine model. We observed that MC38 cancer cells develop significantly faster into tumors when injected into LFS mice (harboring a gain-of-function mutation Trp53R172H/WT) compared to wildtype (WT) control mice. Importantly, we identified significant alterations in immune cell compositions and phenotypes within the tumor microenvironment as well as immune organs using flow cytometry. We are currently using ex vivo proliferation assays and cytotoxicity assays to investigate the impact of mutant p53 on the tumor-killing ability of immune effector cells. Altogether, an improved understanding of anti-tumor immune dysfunction in the context of germline TP53 mutation may reveal the potential for innovative therapies to target different facets of the immune system to intercept cancer progression in LFS patients. Citation Format: Camilla Giovino, Nicholas Fischer, Noel Ong, Ashby Kissoondoyal, Ran Kafri, David Malkin. Characterizing tumor-immune surveillance in Li-Fraumeni syndrome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1533.

oncology
Characteristics of TP53 germline variants and their correlation with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients

Panwen Tian,Xiaoyan Zhang,Sheng Yang,Yu Fang,Hongling Yuan,Wei Li,Honglin Zhu,Fangping Zhao,Jinlei Ding,Yunshu Zhu,Sizhen Wang,Guochen Sun,Hongbin Ni,Tonghui Ma,Ting Lei

DOI: https://doi.org/10.1016/j.jgg.2021.12.012

IF: 5.723

2022-01-01

Journal of Genetics and Genomics

Abstract:Li-Fraumeni syndrome (LFS), a rare autosomal-dominant inheritance condition, is associated with a family cancer history as well as pathogenic/likely-pathogenic TP53 germline variants (P/LP TP53 GV). The current clinical methods for detecting LFS are limited. Here, we retrospectively investigate P/LP TP53 GV among Chinese cancer patients by next-generation sequencing and evaluate its relationship with a family cancer history. A total of 270 out of 19,226 cancer patients have TP53 GV, including 53 patients with P/LP TP53 GV. Patients with P/LP TP53 GV are mainly found in male with glioma, lung cancer or sarcoma. The median age of diagnosis for P/LP TP53 GV patients is significantly lower than that of non-P/LP TP53 GV patients (31-years vs. 53-years; P < 0.01). One LFS patient and 3 Li-Fraumeni-like syndrome (LFL) patients are among the 26 followed-up P/LP TP53 GV patients. Among 25 types of P/LP TP53 GV, the highest variant frequencies occurred at codon 175 and 248. p.M237I, p.R158H, p.C238Y and p.C275R, are firstly identified among the Chinese LFS/LFL patients. This study reports the (P/LP) TP53 GV characteristics of Chinese pan-cancer patients. These findings suggest analyzing the P/LP TP53 GV in cancer patients is an effective strategy for identifying cancer predisposition syndrome.

genetics & heredity,biochemistry & molecular biology
Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns

Derek Wong,Maha Tageldein,Ping Luo,Erik Ensminger,Jeffrey Bruce,Leslie Oldfield,Haifan Gong,Nicholas William Fischer,Brianne Laverty,Vallijah Subasri,Scott Davidson,Reem Khan,Anita Villani,Adam Shlien,Raymond H Kim,David Malkin,Trevor J Pugh

DOI: https://doi.org/10.1038/s41467-024-51529-w

2024-08-27

Abstract:Germline pathogenic TP53 variants predispose individuals to a high lifetime risk of developing multiple cancers and are the hallmark feature of Li-Fraumeni syndrome (LFS). Our group has previously shown that LFS patients harbor shorter plasma cell-free DNA fragmentation; independent of cancer status. To understand the functional underpinning of cfDNA fragmentation in LFS, we conducted a fragmentomic analysis of 199 cfDNA samples from 82 TP53 mutation carriers and 30 healthy TP53-wildtype controls. We find that LFS individuals exhibit an increased prevalence of A/T nucleotides at fragment ends, dysregulated nucleosome positioning at p53 binding sites, and loci-specific changes in chromatin accessibility at development-associated transcription factor binding sites and at cancer-associated open chromatin regions. Machine learning classification resulted in robust differentiation between TP53 mutant versus wildtype cfDNA samples (AUC-ROC = 0.710-1.000) and intra-patient longitudinal analysis of ctDNA fragmentation signal enabled early cancer detection. These results suggest that cfDNA fragmentation may be a useful diagnostic tool in LFS patients and provides an important baseline for cancer early detection.
Characteristics of TP53 Germline Variants and Their Correlations with Li-Fraumeni Syndrome or Li-Fraumeni-like Syndrome in Chinese Tumor Patients

Panwen Tian,Xiaoyan Zhang,Sheng Yang,Yu Fang,Hongling Yuan,Wei Li,Honglin Zhu,Fangping Zhao,Jinlei Ding,Yunshu Zhu,Sizhen Wang,Guochen Sun,Hongbin Ni,Tonghui Ma,Ting Lei

DOI: https://doi.org/10.1016/j.jgg.2021.12.012

2022-01-01

Abstract:Li-Fraumeni syndrome (LFS), a rare autosomal-dominant inheritance condition, is associated with a family cancer history as well as pathogenic/likely-pathogenic TP53 germline variants (P/LP TP53 GV). The current clinical methods for detecting LFS are limited. Here, we retrospectively investigate P/LP TP53 GV among Chinese cancer patients by next-generation sequencing and evaluate its relationship with a family cancer history. A total of 270 out of 19,226 cancer patients have TP53 GV, including 53 patients with P/LP TP53 GV. Patients with P/LP TP53 GV are mainly found in male with glioma, lung cancer or sarcoma. The median age of diagnosis for P/LP TP53 GV patients is significantly lower than that of non-P/LP TP53 GV patients (31-years vs. 53-years; P < 0.01). One LFS patient and 3 Li-Fraumeni-like syndrome (LFL) patients are among the 26 followed-up P/LP TP53 GV patients. Among 25 types of P/LP TP53 GV, the highest variant frequencies occurred at codon 175 and 248. p.M237I, p.R158H, p.C238Y and p.C275R, are firstly identified among the Chinese LFS/LFL patients. This study reports the (P/LP) TP53 GV characteristics of Chinese pan-cancer patients. These findings suggest analyzing the P/LP TP53 GV in cancer patients is an effective strategy for identifying cancer predisposition syndrome.
Hematologic malignancies in Li–Fraumeni syndrome: A case report

Bethany Bundrant,Yoheved Gerstein,Banu Arun,Courtney D. DiNardo

DOI: https://doi.org/10.1002/ajmg.a.63573

2024-02-29

American Journal of Medical Genetics Part A

Abstract:Li–Fraumeni syndrome (LFS) is a rare syndrome characterized by an increased lifetime risk of cancer development in multiple organ systems, typically caused by de novo or inherited germline pathogenic variants in the tumor suppressor TP53 gene. LFS is more classically associated with solid tumors; however, it is also associated with hematologic malignancies such as therapy‐related acute myeloid leukemia (AML). We present the case of a female patient with a strong family and personal history of cancer who presented to our institution with therapy‐related AML with next‐generation sequencing showing a pathogenic TP53 mutation. She received several lines of systemic therapy and underwent stem cell transplant using her adult daughter as a haploidentical donor after achieving minimal residual disease (MRD). Her posttransplant bone marrow evaluations demonstrated persistence of the same pathogenic TP53 mutation despite ongoing clinical remission with full donor engraftment and negative MRD. Genetic testing was performed which confirmed the germline origin of the TP53 pathogenic variant in the patient. The patient's adult donor daughter was also identified to have the same pathogenic variant in TP53 consistent with LFS. The presented case highlights the need for increased awareness of LFS in the adult hematologic community, particularly for patients undergoing evaluation for stem cell transplant.

genetics & heredity
Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

Cristina Fortuno,Bing-Jian Feng,Courtney Carroll,Giovanni Innella,Wendy Kohlmann,Conxi Lázaro,Joan Brunet,Lidia Feliubadaló,Silvia Iglesias,Mireia Menéndez,Alex Teulé,Mandy L. Ballinger,David M. Thomas,Ainsley Campbell,Mike Field,Marion Harris,Judy Kirk,Nicholas Pachter,Nicola Poplawski,Rachel Susman,Kathy Tucker,Mathew Wallis,Rachel Williams,Elisa Cops,David Goldgar,Paul A. James,Amanda B. Spurdle,David Amor,Lesley Andrews,Yoland Antill,Rosemary Balleine,Jonathan Beesley,Ian Bennett,Michael Bogwitz,Simon Bodek,Leon Botes,Meagan Brennan,Melissa Brown,Michael Buckley,Jo Burke,Phyllis Butow,Liz Caldon,Ian Campbell,Michelle Cao,Anannya Chakrabarti,Deepa Chauhan,Manisha Chauhan,Georgia Chenevix-Trench,Alice Christian,Paul Cohen,Alison Colley,Ashley Crook,James Cui,Eliza Courtney,Margaret Cummings,Sarah-Jane Dawson,Anna deFazio,Martin Delatycki,Rebecca Dickson,Joanne Dixon,Ted Edkins,Stacey Edwards,Gelareh Farshid,Andrew Fellows,Georgina Fenton,Michael Field,James Flanagan,Peter Fong,Laura Forrest,Stephen Fox,Juliet French,Michael Friedlander,Clara Gaff,Mike Gattas,Peter George,Sian Greening,Marion Harris,Stewart Hart,Nick Hayward,John Hopper,Cass Hoskins,Clare Hunt,Paul James,Mark Jenkins,Alexa Kidd,Judy Kirk,Jessica Koehler,James Kollias,Sunil Lakhani,Mitchell Lawrence,Jason Lee,Shuai Li,Geoff Lindeman,Jocelyn Lippey,Lara Lipton,Liz Lobb,Sherene Loi,Graham Mann,Deborah Marsh,Sue Anne McLachlan,Bettina Meiser,Roger Milne,Sophie Nightingale,Shona O'Connell,Sarah O'Sullivan,David Gallego Ortega,Nick Pachter,Jia-Min Pang,Gargi Pathak,Briony Patterson,Amy Pearn,Kelly Phillips,Ellen Pieper,Susan Ramus,Edwina Rickard,Bridget Robinson,Mona Saleh,Anita Skandarajah,Elizabeth Salisbury,Christobel Saunders,Jodi Saunus,Peter Savas,Rodney Scott,Clare Scott,Adrienne Sexton,Joanne Shaw,Andrew Shelling,Shweta Srinivasa,Peter Simpson,Melissa Southey,Amanda Spurdle,Jessica Taylor,Renea Taylor,Heather Thorne,Alison Trainer,Kathy Tucker,Jane Visvader,Logan Walker,Rachael Williams,Ingrid Winship,Mary Ann Young,Milita Zaheed,

DOI: https://doi.org/10.1200/po.23.00453

2024-02-01

JCO Precision Oncology

Abstract:PURPOSE Establishing accurate age-related penetrance figures for the broad range of cancer types that occur in individuals harboring a pathogenic germline variant in the TP53 gene is essential to determine the most effective clinical management strategies. These figures also permit optimal use of cosegregation data for classification of TP53 variants of unknown significance. Penetrance estimation can easily be affected by bias from ascertainment criteria, an issue not commonly addressed by previous studies. MATERIALS AND METHODS We performed a maximum likelihood penetrance estimation using full pedigree data from a multicenter study of 146 TP53-positive families, incorporating adjustment for the effect of ascertainment and population-specific background cancer risks. The analysis included pedigrees from Australia, Spain, and United States, with phenotypic information for 4,028 individuals. RESULTS Core Li-Fraumeni syndrome (LFS) cancers (breast cancer, adrenocortical carcinoma, brain cancer, osteosarcoma, and soft tissue sarcoma) had the highest hazard ratios of all cancers analyzed in this study. The analysis also detected a significantly increased lifetime risk for a range of cancers not previously formally associated with TP53 pathogenic variant status, including colorectal, gastric, lung, pancreatic, and ovarian cancers. The cumulative risk of any cancer type by age 50 years was 92.4% (95% CI, 82.2 to 98.3) for females and 59.7% (95% CI, 39.9 to 81.3) for males. Females had a 63.3% (95% CI, 35.6 to 90.1) cumulative risk of developing breast cancer by age 50 years. CONCLUSION The results from maximum likelihood analysis confirm the known high lifetime risk for the core LFS-associated cancer types providing new risk estimates and indicate significantly increased lifetime risks for several additional cancer types. Accurate cancer risk estimates will help refine clinical recommendations for TP53 pathogenic variant carriers and improve TP53 variant classification.

oncology
The Impact of Li Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes and Genetic Testing Recommendations

Josephine K. Dermawan,David H. Abramson,Sarah Chiang,Martee L. Hensley,William D. Tap,Sujana Movva,Robert G. Maki,Diana Mandelker,Cristina R. Antonescu

DOI: https://doi.org/10.1158/1078-0432.ccr-24-1160

IF: 13.801

2024-08-19

Clinical Cancer Research

Abstract:Purpose: Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous, occurring mostly in sporadic but also syndromic settings. The role of pathogenic germline variants (PGV) as LMS drivers and impact on outcome remain uncertain. Experimental Design: We perform a comprehensive clinicopathologic and molecular analysis using a tumor-normal DNA next-generation sequencing assay (MSK-IMPACT) of germline-associated LMS compared to sporadic LMS. Results: Among 285 LMS [120 soft tissue LMS (STLMS), 165 uterine (ULMS)] with germline testing, 78 (27%, 43 STLMS, 35 ULMS) cases harbored PGV: 35/78 (45%) of PGV carriers showing biallelic inactivation of the corresponding gene in the tumor (26 STLMS, 9 ULMS). The most frequent germline predispositions were TP53 (Li-Fraumeni syndrome) (17 patients, 16 in STLMS) and RB1 (retinoblastoma) (13 patients, 11 in STLMS). Germline TP53 and somatic RB1 alterations often co-occurred in the tumor, and vice versa. Other biallelically inactivated PGV were enriched in DNA damage repair-related genes: CHEK2, MSH2, MSH6, RAD51D, BRCA2 and FANCA. Monoallelic PGV were mostly in ULMS and associated with co-occurring TP53 and RB1 somatic alterations. STLMS patients with biallelic but not monoallelic PGV were significantly younger than sporadic STLMS patients (median ages 38 vs 52 vs 58 years). No differences in disease-specific or progression-free survival were observed in germline-associated vs sporadic LMS, regardless of biallelic status. Conclusions: While ULMS patients had a relatively low proportion of PGV, a high percentage of STLMS patients with PGV had tumor biallelic status, indicating that PGV drive tumorigenesis in these individuals. These findings have significant implications for genetic testing recommendations.

oncology
Tumor Spectrum and Temporal Cancer Trends in adult carriers of Li-Fraumeni syndrome: Implications for Personalized Screening Strategies in TP53 R337H carriers

PEDRO A F GALANTE,Gabriela D A Guardia,Janina Pisani,Renata Sandoval,Mateus de Camargo Barros Filho,Ana Carolina Vieira Costa Gifoni,Diogo Ferreira Da Costa Patrao,Patricia Ashton-Prolla,Vitor Fiorin Vasconcellos,Claire Freycon,Arnold Levine,Pierre Hainaut,Maria Isabel Achatz

DOI: https://doi.org/10.1101/2024.06.07.24308605

2024-06-08

Abstract:Background Li-Fraumeni Syndrome (LFS) is a predisposition associated with early onset malignant tumors caused by germline pathogenic variants in the TP53 gene. Although rare worldwide, LFS is prevalent in Southern Brazil due to a founder pathogenic variant, c.1010G>A, p.Arg337His (R337H), discovered through its association with risk of childhood adrenal cortical carcinoma. Methods Here, we have analyzed tumor patterns, cancer risk, sex differences and temporal tumor trends in a cohort of 303 adult R337H carriers and we have compared them with those of 405 adult carriers of other TP53 variants typical of LFS. Findings Compared to the latter, R337H carriers had a lower cumulative risk of developing cancer (54% for R337H vs 78% for other TP53 variants at age 50 years). Female R337H carriers were at a higher risk than males (65% vs 30% at age 50 years) and had a higher risk of developing a second primary cancer, underscoring a strong sex bias not observed in carriers of other variants. The most common cancers were breast (75%), soft tissue sarcoma (9%) and lung cancer (8%) in females, and soft tissue sarcoma (30%), prostate (13%) and lung cancer (12%) in males. Common second malignancies were breast cancer in females and lung cancer in males. Interpretations Overall, this study confirms that R337H is associated with a lifetime risk of multiple cancers of the LFS spectrum but with incomplete penetrance, particularly in males. Our findings suggest that R337H carriers would benefit from adapted lifetime and surveillance strategies for risk reduction.
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis

Christian P Kratz,Claire Freycon,Kara N Maxwell,Kim E Nichols,Joshua D Schiffman,D Gareth Evans,Maria I Achatz,Sharon A Savage,Jeffrey N Weitzel,Judy E Garber,Pierre Hainaut,David Malkin

DOI: https://doi.org/10.1001/jamaoncol.2021.4398

2021-12-01

Abstract:Importance: Li-Fraumeni syndrome is a cancer predisposition syndrome that is associated with a high, lifelong risk of a broad spectrum of cancers that is caused by pathogenic TP53 germline variants. A definition that reflects the broad phenotypic spectrum that has evolved since the gene discovery is lacking, and mechanisms leading to phenotypic differences remain largely unknown. Objective: To define the phenotypic spectrum of Li-Fraumeni syndrome and conduct phenotype-genotype associations across the phenotypic spectrum. Design, setting, and participants: We analyzed and classified the germline variant data set of the International Agency for Research on Cancer TP53 database that contains data on a cohort of 3034 persons from 1282 families reported in the scientific literature since 1990. We defined the term Li-Fraumeni spectrum to encompass (1) phenotypic Li-Fraumeni syndrome, defined by the absence of a pathogenic/likely pathogenic TP53 variant in persons/families meeting clinical Li-Fraumeni syndrome criteria; (2) Li-Fraumeni syndrome, defined by the presence of a pathogenic/likely pathogenic TP53 variant in persons/families meeting Li-Fraumeni syndrome testing criteria; (3) attenuated Li-Fraumeni syndrome, defined by the presence of a pathogenic/likely pathogenic TP53 variant in a person/family with cancer who does not meet Li-Fraumeni syndrome testing criteria; and (4) incidental Li-Fraumeni syndrome, defined by the presence of a pathogenic/likely pathogenic TP53 variant in a person/family without a history of cancer. Data analysis occurred from November 2020 to March 2021. Main outcomes and measures: Differences in variant distribution and cancer characteristics in patients with a germline TP53 variant who met vs did not meet Li-Fraumeni syndrome testing criteria. Results: Tumor spectra showed significant differences, with more early adrenal (n = 166, 6.5% vs n = 0), brain (n = 360, 14.17% vs n = 57, 7.46%), connective tissue (n = 303, 11.92% vs n = 56, 7.33%), and bone tumors (n = 279, 10.98% vs n = 3, 0.39%) in patients who met Li-Fraumeni syndrome genetic testing criteria (n = 2139). Carriers who did not meet Li-Fraumeni syndrome genetic testing criteria (n = 678) had more breast (n = 292, 38.22% vs n = 700, 27.55%) and other cancers, 45% of them occurring after age 45 years. Hotspot variants were present in both groups. Several variants were exclusively found in patients with Li-Fraumeni syndrome, while others where exclusively found in patients with attenuated Li-Fraumeni syndrome. In patients who met Li-Fraumeni syndrome genetic testing criteria, most TP53 variants were classified as pathogenic/likely pathogenic (1757 of 2139, 82.2%), whereas 40.4% (404 of 678) of TP53 variants identified in patients who did not meet the Li-Fraumeni syndrome genetic testing criteria were classified as variants of uncertain significance, conflicting results, likely benign, benign, or unknown. Conclusions and relevance: The findings of this cohort study suggest that this new classification, Li-Fraumeni spectrum, is a step toward understanding the factors that lead to phenotypic differences and may serve as a model for other cancer predisposition syndromes.
Defective Infants and Their Impact on Families: Ethical and Legal Considerations

C. Strong

DOI: https://doi.org/10.1111/j.1748-720X.1983.tb01733.x

1983-08-01

Law Medicine and Health Care

Abstract:o n lulv 5, 1983. the United States Department of Health & Human Services (HHS) proposed a revision of its earlier-issued “Baby Doe rules” on treatment decisions for defective infants.’ Although the initial rules issued by HHS on this topic2 had been struck down by Judge Gerhard Gessell of the United States District Court in April 1983,3 HHS continued the 24-hour hotline,’ and a spokesman declared: “We’re not going to give up.”5 As promised, HHS issued its revised rules less than three months later; the new rules propose a continuation of the hotline and the requirement that medically indicated treatment not be withheld from any handicapped child. These proposed regulations reflect the widespread reproach which has been directed toward physicians and parents who decide to withhold treatment from defective newborns. The Baby Doe case in Bloomington, Indiana, which precipitated the HHS rules, is the most recent example. This case involved an infant with Down syndrome and an esophageal atresia, which required treatment if the infant were to survive. Media coverage resulted in nationwide condemnation of the parents’ decision to withhold corrective surgery. A n Indiana state representative was quoted: “Certainly the child has a right to life. 1 can’t imagine any court denying the child a chance to live.”6 The HHS Office for Civil Rights
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.

Jung Kim,Matthew Gianferante,Danielle M. Karyadi,Stephen W. Hartley,Megan N. Frone,Wen Luo,Leslie L. Robison,Gregory T. Armstrong,Smita Bhatia,Michael Dean,Meredith Yeager,Bin Zhu,Lei Song,Joshua N. Sampson,Yutaka Yasui,Wendy M. Leisenring,Seth A. Brodie,Kelvin C. de Andrade,Fernanda P. Fortes,Alisa M. Goldstein,Payal P. Khincha,Mitchell J. Machiela,Mary L. McMaster,Michael L. Nickerson,Leatrisse Oba,Alexander Pemov,Maisa Pinheiro,Melissa Rotunno,Karina Santiago,Talia Wegman-Ostrosky,W. Ryan Diver,Lauren Teras,Neal D. Freedman,Belynda D. Hicks,Mingyi Wang,Kristine Jones,Amy A. Hutchinson,Casey Dagnall,Sharon A. Savage,Margaret A. Tucker,Stephen J. Chanock,Lindsay M. Morton,Douglas R. Stewart,Lisa Mirabello

DOI: https://doi.org/10.1093/jncics/pkab007

2021-01-01

JNCI Cancer Spectrum

Abstract:Background:Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study.Methods:Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons.Results:Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided P = 3 × 10-4). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including BRCA1/2, FH, PALB2, PMS2, and CDKN2A. A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (NF1, SUFU, TSC1, PTCH2), Wilms tumor (WT1, REST), non-Hodgkin lymphoma (PMS2), and soft tissue sarcomas (SDHB, DICER1, TP53, ERCC4, FGFR3) compared with other pediatric cancers.Conclusion:In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families.
Variant Clusters Stratify the Li-Fraumeni Spectrum and Reveal an Osteosarcoma-Prone Subgroup

Nicholas W Fischer,Brianne Laverty,Noa Alon,Emilie Montellier,Kara N Maxwell,Christian P Kratz,Pierre Hainaut,Ran Kafri,David Malkin

DOI: https://doi.org/10.1101/2024.01.06.23300162

2024-01-07

Abstract:Li-Fraumeni syndrome (LFS) has recently been redefined as a ‘spectrum’ cancer predisposition disorder to reflect its broad phenotypic heterogeneity. The wide functional gradient associated with different variants is thought to contribute to LFS heterogeneity, although it is still poorly understood and there is an unmet clinical need for risk stratification strategies. Leveraging p53 mutagenesis dataset, we performed an unsupervised cluster analysis that revealed five variant clusters with unique structural and functional consequences. Classifying variant carriers according to these clusters stratified cancer onset and survival using discovery and validation cohorts, and exposed important clinical characteristics to consider for patient management. In particular, we identified a subgroup of monomeric variant carriers prone to osteosarcoma, along with a cluster associated with less “LFS-like” phenotypes enriched in carriers with no history of cancer. Our classification of variants demonstrates the existence of a wide heritable cancer susceptibility spectrum and provides a new framework to delineate carriers toward personalized patient care.

Oncology
Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study

Mena Louis,Jerrell Fang,Nathaniel Grabill,Hardeep Singh,Priscilla Strom

DOI: https://doi.org/10.1016/j.ijscr.2024.110323

Abstract:Introduction and importance: Li-Fraumeni syndrome (LFS) is a rare hereditary disorder caused by mutations in the TP53 gene, leading to a significantly increased risk of developing various cancers at a young age, including breast cancer. Clinical presentation: This case report details the clinical journey of a 21-year-old female diagnosed with Grade 3 invasive ductal carcinoma, which was estrogen receptor low positive and progesterone receptor negative but positive for Her2 (3+) with a high Ki67 proliferation index. Clinical discussion: Genetic testing confirmed a TP53 mutation, establishing the diagnosis of LFS. The patient underwent neoadjuvant chemotherapy with TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab), resulting in a complete clinical response. This was followed by bilateral skin-sparing and nipple-sparing mastectomy with sentinel lymph node biopsy and immediate reconstruction. Postoperative pathology confirmed a complete response to neoadjuvant therapy. The patient's treatment plan includes 12 cycles of trastuzumab and pertuzumab, with regular echocardiograms to monitor cardiac function and fertility preservation strategies involving monthly Lupron injections. Given the association of LFS with a high risk of multiple primary cancers, a rigorous surveillance strategy is essential. The psychological impact of a cancer diagnosis and the burden of living with a hereditary cancer syndrome were significant, necessitating comprehensive psychosocial support. Conclusion: Managing Li-Fraumeni syndrome (LFS) and its associated cancers, particularly in young patients, necessitates a comprehensive and multidisciplinary approach. Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies.
Li-Fraumeni Syndrome: Imaging Features and Guidelines

Babina Gosangi,Irene Dixe de Oliveira Santo,Abhishek Keraliya,Yifan Wang,David Irugu,Richard Thomas,Ashish Khandelwal,Ami N Rubinowitz,Anna S Bader

DOI: https://doi.org/10.1148/rg.230202

Radiographics

Abstract:Li-Fraumeni syndrome (LFS) is a rare autosomal dominant familial cancer syndrome caused by germline mutations of the tumor protein p53 gene (TP53), which encodes the p53 transcription factor, also known as the "guardian of the genome." The most common types of cancer found in families with LFS include sarcomas, leukemia, breast malignancies, brain tumors, and adrenocortical cancers. Osteosarcoma and rhabdomyosarcoma are the most common sarcomas. Patients with LFS are at increased risk of developing early-onset gastric and colon cancers. They are also at increased risk for several other cancers involving the thyroid, lungs, ovaries, and skin. The lifetime risk of cancer in individuals with LFS is greater than 70% in males and greater than 90% in females. Some patients with LFS develop multiple primary cancers during their lifetime, and guidelines have been established for screening these patients. Whole-body MRI is the preferred modality for annual screening of these patients. The management guidelines for patients with LFS vary, as these individuals are more susceptible to developing radiation-induced cancers-for example, women with LFS and breast cancer are treated with total mastectomy instead of lumpectomy with radiation to the breast. The authors review the role of imaging, imaging guidelines, and imaging features of tumors in the setting of LFS. ©RSNA, 2024 Supplemental material is available for this article.

Diagnostic difficulties in rectosigmoid lesions.

EphA 3 , induced by PC1 / PrLZ , contributes to the malignant progression of prostate cancer

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA

Abstract 6198: TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome

Abstract 810: Enrichment and Screening of LFS Patients by Analyzing TP53 Germline Mutations of a Chinese Cancer Cohort

Distinct genomic and immunologic tumor evolution in germline driven breast cancers

Abstract 1533: Characterizing tumor-immune surveillance in Li-Fraumeni syndrome

Characteristics of TP53 germline variants and their correlation with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients

Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns

Characteristics of TP53 Germline Variants and Their Correlations with Li-Fraumeni Syndrome or Li-Fraumeni-like Syndrome in Chinese Tumor Patients

Hematologic malignancies in Li–Fraumeni syndrome: A case report

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

The Impact of Li Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes and Genetic Testing Recommendations

Tumor Spectrum and Temporal Cancer Trends in adult carriers of Li-Fraumeni syndrome: Implications for Personalized Screening Strategies in TP53 R337H carriers

Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis

Defective Infants and Their Impact on Families: Ethical and Legal Considerations

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.

Variant Clusters Stratify the Li-Fraumeni Spectrum and Reveal an Osteosarcoma-Prone Subgroup

Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study

Li-Fraumeni Syndrome: Imaging Features and Guidelines